NCT01159561

Western Equine Encephalitis Vaccine, Inactivated

Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: U.S. Army Medical Research and Development Command · Federal
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is designed to determine the safety and immunogenicity of WEE Vaccine Lot number 3-1-92.

Detailed description

Study Objectives: Primary: To assess safety of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92. Secondary: To evaluate immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92.

Conditions

• Virus

Interventions

Type	Name	Description
BIOLOGICAL	Western Equine Encephalitis Vaccine	Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.

Timeline

• Start date: 2010-02-01
• Primary completion: 2011-08-01
• Completion: 2012-03-01
• First posted: 2010-07-09
• Last updated: 2019-04-29

Locations

1 site across 1 country: United States